{"id":545749,"date":"2021-06-01T20:54:02","date_gmt":"2021-06-01T20:54:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545749"},"modified":"2021-06-01T20:54:02","modified_gmt":"2021-06-01T20:54:02","slug":"inclusion-body-myositis-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/inclusion-body-myositis-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_545749.html","title":{"rendered":"Inclusion Body Myositis Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Inclusion<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cInclusion Body Myositis\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Inclusion Body Myositis, historical and forecasted epidemiology as well as the Inclusion Body Myositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Inclusion Body Myositis-Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Inclusion Body Myositis–Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Inclusion Body Myositis, historical and forecasted epidemiology as well as the Inclusion Body Myositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

 <\/p>\n

    \n
  1. \n

    A study specified that recent work estimated the population prevalence of sporadic IBM in Northern Europe to 3.3\/100 000, which is higher than in previous studies.<\/p>\n<\/li>\n

  2. \n

    According to Orphanet, Inclusion body myositis (IBM) has a highly variable prevalence according to geographic, ethnic and age criteria. Prevalence in the general population ranges from 1\/14,000-1,000,000 but a three-fold increase is observed when considering only a population over 50 years. Underdiagnosis may be an explanation for the high ethno-geographic variation. The male-to-female ratio is 2:1 on average (but varies between 0.5 to 6.5:1).  <\/p>\n<\/li>\n

  3. \n

    A study quoted that data from Japan indicated that the prevalence was less than 10 per million in 2003, but rising towards 2012.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.The Inclusion Body Myositis market report covers a descriptive overview and comprehensive insight of the Inclusion Body Myositis epidemiology and Inclusion Body Myositis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.The Inclusion Body Myositis market report provides insights into the current and emerging therapies.<\/p>\n

    3.Inclusion Body Myositis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4.The Inclusion Body Myositis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Inclusion Body Myositis market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/inclusion-body-myositis-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Inclusion Body Myositis: Overview<\/strong><\/p>\n

    Inflammation of myositis (IBM) is a prescription treatment that demonstrates the treatment of middle-aged patients leading to slow, chronic muscle weakness, and atrophy. It belongs to a group of inflammatory myopathies, including dermatomyositis (DM), polymyositis (PM), necrotizing myopathy, and chronic myositis. IBM patients are mostly over 50 years old at the first launch.<\/p>\n

    The key players involved in the Inclusion Body Myositis market<\/a>:<\/strong><\/p>\n

     <\/p>\n

      \n
    1. \n

      Orphazyme<\/p>\n<\/li>\n

    2. \n

      Alzehon<\/p>\n<\/li>\n

    3. \n

      Kv1.3 Therapeutics <\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Inclusion Body Myositis treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        Arimoclomol<\/p>\n<\/li>\n

      2. \n

        ALZ-507<\/p>\n<\/li>\n

      3. \n

        Dalazatide<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @ https:\/\/www.delveinsight.com\/sample-request\/inclusion-body-myositis-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Inclusion Body Myositis Patient Share (%) Overview at a Glance<\/p>\n

        5. Inclusion Body Myositis Market Overview at a Glance<\/p>\n

        6. Inclusion Body Myositis Disease Background and Overview<\/p>\n

        7. Inclusion Body Myositis Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Inclusion Body Myositis <\/p>\n

        9. Inclusion Body Myositis Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Inclusion Body Myositis Emerging Therapies<\/p>\n

        12. Inclusion Body Myositis Market Outlook<\/p>\n

        13. Country-Wise Inclusion Body Myositis Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Inclusion Body Myositis Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cInclusion Body Myositis\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Inclusion Body Myositis, historical and forecasted epidemiology as well as the Inclusion Body Myositis market trends in the United States, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-545749","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545749"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545749\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}